SCHEMBL18691828

SCHEMBL18691828

CCOC(=O)CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.59
▸ STAT3 P40763 6/20 0.59
▸ MAPT P10636 6/20 0.47
▸ LMNA P02545 6/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ APAF1 O14727 1/20 0.47
▸ MITF O75030 1/20 0.47
▸ GABRP O00591 1/20 0.41
▸ GABRD O14764 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ GABRG2 P18507 1/20 0.41
▸ GABRB3 P28472 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ GABRA2 P47869 1/20 0.41
▸ GABRB2 P47870 1/20 0.41
▸ GABRA4 P48169 1/20 0.41
▸ GABRE P78334 1/20 0.41
▸ GABRA6 Q16445 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18730814 0.93 STAT3 (0.52) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL17345532 0.92 ALDH1A1 (0.53) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL18807113 0.90 STAT3 (0.57) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL17345519 0.89 STAT3 (0.53) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL18730823 0.89 STAT3 (0.56) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL17345518 0.89 ALDH1A1 (0.50) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL17345477 0.88 STAT3 (0.64) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL18807118 0.88 STAT3 (0.54) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL18691820 0.88 STAT3 (0.57) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL17345553 0.88 STAT3 (0.60) ALDH1A1STAT3MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11267797-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2022-03-08 — — US disclosed
US-11267797-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2022-03-08 — — US disclosed
US-20200317630-A1 ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2020-10-08 — — US disclosed
US-20200317630-A1 ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2020-10-08 — — US disclosed
US-10689355-B2 Anticancer agent Kyoto Pharmaceuticals Industries, Ltd. (JP) 2020-06-23 — — US disclosed
US-10689355-B2 Anticancer agent Kyoto Pharmaceuticals Industries, Ltd. (JP) 2020-06-23 — — US disclosed
EP-3153508-B1 NAPHTHOFURAN DERIVATIVES FOR USE AS ANTICANCER AGENTS KYOTO PHARMA IND (JP) 2020-03-18 — — EP disclosed
US-20190322636-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2019-10-24 — — US disclosed
US-20190322636-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2019-10-24 — — US disclosed
US-10377730-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2019-08-13 — — US disclosed
US-10377730-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2019-08-13 — — US disclosed
US-20180265489-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2018-09-20 — — US disclosed
US-10005752-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2018-06-26 — — US disclosed
US-10005752-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2018-06-26 — — US disclosed
US-10005752-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2018-06-26 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
EP-3153508-A1 NOVEL ANTICANCER AGENT Kyoto Pharmaceutical Industries, Ltd. (JP) 2017-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121299-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885
US-20200317630-A1 ANTICANCER AGENT TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-10005752-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-11267797-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-20180265489-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885
US-20190322636-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885
US-10689355-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-10377730-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback